Osteogenic Growth Peptide (10-14) trifluoroacetate salt

Modify Date: 2024-01-02 19:35:01

Osteogenic Growth Peptide (10-14) trifluoroacetate salt structure	Common Name	Osteogenic Growth Peptide (10-14) trifluoroacetate salt
	CAS Number	105250-85-9	Molecular Weight	499.51600
	Density	1.352g/cm3	Boiling Point	1028ºC at 760mmHg
	Molecular Formula	C₂₄H₂₉N₅O₇	Melting Point	N/A
	MSDS	N/A	Flash Point	575.5ºC

Use of Osteogenic Growth Peptide (10-14) trifluoroacetate salt

Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Src inhibitor[1][2][3][4].

Name	Osteogenic Growth Peptide (10-14)
Synonym	More Synonyms

Description	Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Src inhibitor[1][2][3][4].
Related Catalog	Research Areas >> Others Signaling Pathways >> Protein Tyrosine Kinase/RTK >> Src
In Vitro	Osteogenic Growth Peptide (10-14) (OGP(10-14)) induces proliferation and differentiation in fibroblast and osteoblast cell lines[3]. Osteogenic Growth Peptide (10-14) induces TPO-primed M07-e cells differentiation through RhoA/TGFβ1/SFKs signalling pathway. In particular Historphin acts as a Src inhibitor, showing the same effects of PP2[4].
In Vivo	Osteogenic Growth Peptide (10-14) (OGP(10-14)) increases bone formation and trabecular bone density and stimulates fracture healing when administered to mice and rats[1].
References	[1]. Chen YC, et al. Bioactive pseudopeptidic analogues and cyclostereoisomers of osteogenic growth peptide C-terminal pentapeptide, OGP(10-14). J Med Chem. 2002;45(8):1624-1632. [2]. Chen Z, et al. Regulation of endochondral ossification by osteogenic growth peptide C-terminal pentapeptide [OGP(10-14)]. Protein Pept Lett. 2009;16(9):1074-1080. [3]. Fazzi R, et al. Bone and bone-marrow interactions: haematological activity of osteoblastic growth peptide (OGP)-derived carboxy-terminal pentapeptide. Mobilizing properties on white blood cells and peripheral blood stem cells in mice. Leuk Res. 2002;26(1):19-27. [4]. Battolla B, et al. The small peptide OGP(10-14) reduces proliferation and induces differentiation of TPO-primed M07-e cells through RhoA/TGFbeta1/SFK pathway. Med Sci Monit. 2011;17(1):SC1-SC5.

Density	1.352g/cm3
Boiling Point	1028ºC at 760mmHg
Molecular Formula	C₂₄H₂₉N₅O₇
Molecular Weight	499.51600
Flash Point	575.5ºC
Exact Mass	499.20700
PSA	199.95000
LogP	0.68660
Vapour Pressure	0mmHg at 25°C
Index of Refraction	1.609